Balyasny Asset Management
NGNE icon

Balyasny Asset Management’s Neurogene NGNE Stock Holding History

Balyasny Asset Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.5M Buy
718,389
+109,811
+18% +$2.13M 0.02% 838
2025
Q4 		$12.5M Sell
608,578
-90,424
-13% -$2.25M 0.02% 926
2025
Q3 		$12.1M Buy
+699,002
New +$14M 0.02% 955
2020
Q4 		– Sell
-5,500
Closed -$1.32M – 1581
2020
Q3 		$1.32M Buy
5,500
+2,000
+57% +$484K 0.01% 941
2020
Q2 		$1.16M Buy
3,500
+2,590
+285% +$675K 0.01% 802
2020
Q1 		$207K Sell
910
-4,127
-82% -$849K ﹤0.01% 1047
2019
Q4 		$1.24M Buy
+5,037
New +$502K 0.01% 846

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Balyasny Asset Management's NGNE Position: Q1 2026 in Review

Balyasny Asset Management increased its Neurogene (NGNE) stake by 18% in Q1 2026, buying an estimated $2.13M and bringing the position to 718,389 shares worth $14.5M. The position accounts for 0.02% of the portfolio, ranked #838.

Balyasny Asset Management first reported a position in NGNE in Q4 2019 and has held it in 7 quarters since. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Balyasny Asset Management held 718,389 shares of Neurogene worth $14.5M as of Q1 2026.
  • Balyasny Asset Management bought 109,811 Neurogene shares in Q1 2026, an estimated $2.13M.
  • Neurogene made up 0.02% of Balyasny Asset Management's portfolio in Q1 2026, its #838 holding.
  • Balyasny Asset Management first reported a position in Neurogene in Q4 2019 and has held it in 7 quarters since.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.